India, Oct. 21 -- Dr. Reddy's Laboratories has received approval from the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), for Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel as a first-line treatment for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
This marks the drug's second approved indication in India, following its approval for nasopharyngeal carcinoma. The company had entered into a licensing and commercialisation agreement with Junshi Biosciences in 2023 to market toripalimab across 21 countries.
Toripalimab has also received approvals from regulatory authorities in the US, Europe and the UK. The...